> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Angiotensin II Receptor Blocker Impurities Q&A
- URL: https://www.fdaweb.com/angiotensin-ii-receptor-blocker-impurities-q-a/
- Published: 2018-11-20T12:00:00.000Z
- Updated: 2026-09-15T00:45:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142857

FDA has posted online questions and answers about impurities found in certain generic angiotensin II receptor blocker products. Beginning in June, the agency says, it found that some generic versions of the prescription drug valsartan contained unexpected impurities that posed a safety concern. The [document](https://www.fda.gov/Drugs/DrugSafety/ucm626122.htm?utm%5Fcampaign=FDA%20posts%20Questions%20and%20Answers%20for%20impurities%20found%20in%20certain%20generic%20ARB%20products&utm%5Fmedium=email&utm%5Fsource=Eloqua#info) says the impurities, N-Nitrosodimethylamine and N-Nitrosodiethylamine, are probable human carcinogens.

All products found to contain the impurities have been recalled, the notice says, and are no longer available in the U.S. market.

The post goes into detail on the nature of the impurities, how they got into the drugs, whether they could be in other drugs, risks to patients, and FDA’s actions to date and future actions.